Prevnar, Effexor, Enbrel Powering Strong First Quarter For Wyeth
This article was originally published in The Pink Sheet Daily
Executive Summary
Normalization of Prevnar demand after the correction of supply problems will play a major role in delivering first quarter earnings per share levels significantly higher than analyst estimates, CFO Martin says. Third quarter results may be down compared to 2004 because of high anticipated R&D spending.
You may also be interested in...
Wyeth Sales Force Reorganization Will Not Wait For Competitive Response
Wyeth says it does not have an internal goal for the number of positions to be cut in its primary care sales force. The company raises its 2005 earnings guidance based on favorable sales trends.
Wyeth Sales Force Reorganization Will Not Wait For Competitive Response
Wyeth says it does not have an internal goal for the number of positions to be cut in its primary care sales force. The company raises its 2005 earnings guidance based on favorable sales trends.
Protonix Average Price Increases By 8% As Wyeth Cuts Medicaid Contracts
Focus on key managed care accounts and elimination of some state contracts has resulted in an 8% weighted average price increase compared to first quarter 2004. Protonix shows 10% total prescription growth, but posts flat sales due to 9% inventory workdown.